|
[1] 田如月，李广欣，曹邦伟.多靶点酪氨酸激酶抑制剂瑞戈非尼在实体瘤中的临床应用进展[J].中国医院用药评价与分析，2017，17(8)：1011-1012，1016.
[2] Bekaii-Saab, TS，Ou,
FS，Ahn, DH, et
al.Regorafenib dose-optimisation in patients with refractory metastatic
colorectal cancer (ReDOS)：a randomised, multicentre,
open-label, phase 2 study.Lancet Oncol，2019，20(8)：1070-1082.
[3] 李博，高蕊，李睿，等.药物临床试验不良反应/不良事件关联性判定方法研究探讨[J].中药新药杂志，2014，23(12)：1465-1470.
[4] Li J, Qin S, Xu R, et al. Regorafenib plus
best supportive care versus placebo plus best supportive care in Asian patients
with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind,
placebo-controlled, phase 3 trial[J]. Lancet Oncology, 2015，16(6)：619-629.
[5] Karen S, Su G，Abeed
S，et al. Methods to
Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and
Systematic Reviews: Proof of Concept with Adalimumab[J].Drug Safety, 2018, 41(12)：1397-1410
[6] Bin Zhao，Hong
Zhao.Incidence and risk of hematologic toxicities in cancer patients treated
with regorafenib[J].Oncotarget, 2017, 8(55): 93813-93824 .
[7] Gao WJ, Liu YY，Yuan
CR. International evaluation system for adverse events of chemotherapeutic
drugs in cancer treatment：CTCAE v4./0[J].Tumor, 2012,
32(2)：142-144.
[8] 卫晓晓，吴萍，王瑛，等.1例肺癌患者化疗致Ⅳ度骨髓抑制的病例分析[J].海峡药学，2021，33(2)，198-200.
[9] 史艳侠，
邢镨元， 张俊，等.中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019版)[J]. 中国肿瘤临床， 2019(18)：923-929.
[10] Cheng Han，Huang
Jing，Wu Jin，et al.Meta-analysis of
recombinant human thrombopoietin in treatment of chemotherapy induced
thrombocytopenia in patients with malignancy[J].Hainan Medical Journal，2020, 31(17)：2276-2284.
[11]
British Committee for Standards in
Haematology, Blood Transfusion Task Force.Guidelines for the use of platelet
transfusions[J]. British Journal of Haematology，2017，176(3)：365-394.
[12] Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C,
et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe
thrombocytopenia and the need for platelet transfusions in patients with
gynecologic cancer[J]. Annals of Internal Medicine，2000，132(5)：364-368.
|
